905 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
GSK GlaxoSmithKline PLC $39.21 $97.25B Uptrend
Article Searches
Johnson & Johnson (JNJ) to Acquire Auris Health for $3.4B http://www.zacks.com/stock/news/354868/johnson-johnson-jnj-to-acquire-auris-health-for-%2434b?cid=CS-ZC-FT-354868 Feb 14, 2019 - Johnson & Johnson (JNJ) entered into a definitive agreement to acquire Auris Health, Inc., a developer of robotic technologies focused on lung cancer, for approximately $3.4 billion in cash.
Top Ranked Income Stocks to Buy for February 14th http://www.zacks.com/commentary/213612/top-ranked-income-stocks-to-buy-for-february-14th?cid=CS-ZC-FT-213612 Feb 14, 2019 - Top Ranked Income Stocks to Buy for February 14th
New Strong Buy Stocks for February 14th http://www.zacks.com/commentary/213348/new-strong-buy-stocks-for-february-14th?cid=CS-ZC-FT-213348 Feb 14, 2019 - New Strong Buy Stocks for February 14th
AstraZeneca's (AZN) Q4 Earnings Beat, New Drugs Drive Sales http://www.zacks.com/stock/news/354603/astrazenecas-azn-q4-earnings-beat-new-drugs-drive-sales?cid=CS-ZC-FT-354603 Feb 14, 2019 - AstraZeneca (AZN) beats earnings and sales estimates in the fourth quarter and provides encouraging outlook for 2019. Shares up.
Merck's Keytruda Gets FDA Priority Review for Head/Neck Cancer http://www.zacks.com/stock/news/353843/mercks-keytruda-gets-fda-priority-review-for-head-neck-cancer?cid=CS-ZC-FT-353843 Feb 12, 2019 - Merck's (MRK) supplemental biologics license application for Keytruda receives a priority review from the FDA for the first-line treatment of patients with recurrent/metastatic head and neck cancer.
Acer Therapeutics: Multiple Aces Up Its Sleeve https://seekingalpha.com/article/4240028-acer-therapeutics-multiple-aces-sleeve?source=feed_sector_healthcare Feb 11, 2019 - Acer announced on December 26, 2018 that the FDA had accepted Acer's NDA for EDSIVO for review for the treatment of vEDS.The FDA also granted priority review of the EDSIVO NDA with a PDUFA target acti
By Besting Herceptin, The Future Is Bright For MacroGenics https://seekingalpha.com/article/4239967-besting-herceptin-future-bright-macrogenics?source=feed_sector_healthcare Feb 11, 2019 - Margetuximab has blockbuster potential boding well for MacroGenics as the data support initiation of a head to head trial in the first line.Yet again, the analysts were wrong.A wealth of preclinical a
GlaxoSmithKline And Merck KGaA Position For The Next Wave In Immuno-Oncology https://seekingalpha.com/article/4239823-glaxosmithkline-merck-kgaa-position-next-wave-immuno-oncology?source=feed_sector_healthcare Feb 11, 2019 - GSK collaborates with Merck KGaA on M7824, a TGF-beta.M7824 represents a class of agents considered to be the future of Immuno-Oncology.Late stage trials are needed to validate, M7824; if successful,
Pharma Stock Roundup: Q4 Earnings at MRK, LLY, CHMP Nod for Several Drugs http://www.zacks.com/stock/news/353203/pharma-stock-roundup-q4-earnings-at-mrk-lly-chmp-nod-for-several-drugs?cid=CS-ZC-FT-353203 Feb 08, 2019 - Merck (MRK) and Lilly (LLY) report Q4 results. CHMP gives nod to several drugs.
GlaxoSmithKline (GSK) CEO Emma Walmsley on Q4 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4238727-glaxosmithkline-gsk-ceo-emma-walmsley-q4-2018-results-earnings-call-transcript?source=feed_sector_healthcare Feb 06, 2019 - GlaxoSmithKline (NYSE:GSK) Q4 2018 Results Conference Call February 06, 2019 09:00 AM ET Company Participants Sarah Elton-Farr - Head of Investor Relations Emma Walmsley - Chief Executive Officer Simo

Pages: 1234567...91

<Page 2>